Asoprisnil
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H35NO4 |
Molar mass | 449.591 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
NY (what is this?) (verify) |
Asoprisnil (INN; developmental code name J-867) is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids.[1] In 2005, phase III clinical trials were discontinued due to endometrial changes in patients.[2]
See also
References
- ↑ DeManno D, Elger W, Garg R, et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids. 68 (10–13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995. S2CID 23074350.
- ↑ Schering Interim Report Q1-3 2005
Progesterone receptor modulators | |||||||
---|---|---|---|---|---|---|---|
PR |
| ||||||
mPR (PAQR) |
| ||||||
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.